- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AHA Fears Tightening of Antitrust Restrictions Regarding ACOs
On January 3, the AHA noted in a response to a public request for comment that it was disappointed (PDF) in a little-noticed announcement from the Centers for Medicare & Medicaid Services (CMS) that it planned to tighten some ACO fraud-and-abuse waivers by narrowing legal definitions after two years of experience with the program.
Read the full story at: http://tinyurl.com/8xxdqw9
Source: Modern Healthcare
The AHA urged CMS to declare that it would only make material changes to the rules after a public notice-and-comment period. “ACOs should not be at risk for changes to the rules through obscure or little noticed issuances,” the AHA letter said.
Although observers roundly praised federal officials for loosening the antitrust and abuse rules on accountable care organizations (ACOs), the American Hospital Association (AHA) is protesting what it says are efforts by regulators to move back toward stricter enforcement over time.
A meta-analysis showed that control group outcomes in psilocybin trials for depression were significantly weaker than those in selective serotonin reuptake inhibitor (SSRI) and esketamine trials, suggesting that psilocybin’s large observed treatment effects may be inflated by methodological factors such as functional unblinding and expectancy bias.
Read More
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
